Yazar "Yesin, Mahmut" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim
    Öğe
    Association between BNP levels and new-onset atrial fibrillation: A propensity score approach
    (Urban & Vogel, 2018) Karaba?, Yavuz; Rencüzoğulları, İbrahim; Ça?daş, Metin; Karakoyun, Süleyman; Yesin, Mahmut; Uluganyan, Mahmud; Gürsoy, Mustafa Ozan; Artaç, İnanç; İliş, Do?an; Gökdeniz, Tayyar; Efe, Süleyman Çağan; Taşar, Onur; Tanbo?a, Halil İbrahim
    New-onset atrial fibrillation (NOAF), a common complication of acute ST-segment elevation myocardial infarction (STEMI), is associated with a poor prognosis. Several clinical and laboratory parameters are reported to be associated with NOAF in patients with STEMI. The aim of the present study was to evaluate the predictive value of plasma BaEurotype natriuretic peptide (BNP) levels for NOAF development and long-term prognosis in STEMI patients undergoing primary percutaneous coronary intervention (pPCI). We retrospectively enrolled 1,928 patients with STEMI who underwent pPCI. After applying exclusion criteria, 1,057 patients were retained in the final study population. Patients with NOAF were compared with patients without NOAF in the entire study population and in a matched group. Patients with NOAF had a significantly higher average plasma BNP level (161 pg/ml, range: 72.3-432) than patients without NOAF in the study population (70.7 pg/ml, range: 70-129; p <0.001) and in the matched group (104.6 pg/ml, range: 47.2-234.5; p = 0.014). Furthermore, the plasma BNP level was found to be an independent predictor of NOAF development (odds ratio [OR]: 1.003; 95% confidence interval [CI]: 1.000-1.005; p = 0.034) and mortality in the long-term follow-up (OR: 1.004; 95% CI: 1.002-1.006; p <0.001). The present study found that a high plasma BNP level was significantly associated with NOAF development in STEMI patients, and was an independent predictor of NOAF development and all-cause mortality during long-term follow-up, regardless of other NOAF risk factors.
  • Küçük Resim
    Öğe
    Comparison of SYNTAX score II efficacy with SYNTAX score and TIMI risk score for predicting in-hospital and long-term mortality in patients with ST segment elevation myocardial infarction
    (Springer, 2018) Karabağ, Yavuz; Çağdaş, Metin; Rencuzoğulları, İbrahim; Karakoyun, Süleyman; Artaç, İnanç; İliş, Doğan; Yesin, Mahmut; Öterkuş, Mesut; Gökdeniz, Tayyar; Burak, Cengiz; Tanboğa, İbrahim Halil
    SYNTAX score II (SS-II) has a powerful prognostic accuracy in patients with stable complex coronary artery disease who have undergone revascularization; however, there is limited data regarding the prognosis of patients with ST segment elevation myocardial infarction (STEMI). The aim of this study is to examine both the predictive performance of SS-II in determining in-hospital and long term mortality of STEMI patients and to compare SYNTAX score (SS) and TIMI risk score (TRS). Consecutive 1912 STEMI patients treated with primary percutaneous coronary intervention (p-PCI) retrospectively reviewed, and the remaining 1708 patients constituted the study population after exclusion. The patients were divided into three groups according to increased SS-II value: low (n:562; SS-II <= 24.6); intermediate (n:563; 24.6 = 34.4). In-hospital and long term mortality rate from all causes (0 vs. 0.5 vs. 10.6% and 1.8 vs. 3.2 vs. 18.1% respectively, p <= 0.001) were significantly increased with SS-II tertiles and SS-II was found to be independent predictor of in-hospital and long term mortality (HR: 1.076 95% CI 1.060-1.092, p <0.001) and (HR: 1.070 95% CI 1.050-1.090, p <0.0001). The predictive power of SS-II, SS, and TRS were compared by ROC curve and decision curve analysis. SS-II surpassed SS and TRS in long-term and in-hospital mortality prediction. SS-II is a powerful tool to predict in-hospital and long-term mortality from all causes in STEMI patients treated with p-PCI.
  • Küçük Resim
    Öğe
    Demographics of patients with heart failure who were over 80 years old and were admitted to the cardiology clinics in Turkey
    (Turkish Society of Cardiology, 2019) Gök, Gülay; Zoghi, Mehdi; Sinan, Ümit Yaşar; Kılıç, Salih; Tokgözoğlu, Lale; Sümerkan, Mutlu Çağan; Emren, Volkan; Bekar, Lütfü; Cerşit, Sinan; Tunç, Elif; Ulucan, Şeref; Altuntaş, Emine; Canpolat, Uğur; Özmen, Namık; Açıksarı, Gönül; Doğan, Nazile Bilgin; Günay, Şeyda; Kemaloğlu, Meltem Didem; Nacar, Alper Buğra; Karakoyun, Süleyman; İnci, Sinan; Özlek, Bülent; Aslan, Onur; Baykız, Derya; Gündüz, Sabahattin; Köroğlu, Sedat; Helvacı, Ayşen; Coşkun, Raşit; Yüksel, İsa Öner; Çetin, Şükrü; Yesin, Mahmut; Gürsoy, Mustafa Ozan; Çatırlı Enar, Sibel; Tek Öztürk, Müjgan; Yılmaz, Aykut; Başaran, Özcan; Okyay, Kaan; Öztürk, Cengiz; Çelik, Oğuzhan; Yalçınkaya, Emre; Aslan, Vedat; Şenol, Utku; Uçar, Fatih Mehmet; Kozluca, Volkan; Türkoğlu, Ebru İpek; Şekuri, Cevat; Ertürk, Mehmet; Altun, İbrahim; Belen, Erdal; Aksan, Gökhan; Yıldırım, Erkan; Sayın, Ahmet; Akkoyun, Dursun Çayan; Tunçez, Abdullah; Doğan, Volkan; Gürel, Yusuf Emre; Demirelli, Selami; Koca, Çiğdem; Biteker, Murat; Bas, Hasan Aydın; Güzet, Feza; Taçoy, Gülten; Alpsoy, Şeref; Turan, Turhan; Davutoğlu, Vedat; Birdane, Alparslan; Onrat, Ersel; Baha, Mehmet Reşat; Yılmaz, Sabiye; Altay, Servet; Alıcı, Mehmet Hayri; Özcan, İsmail Türkay; Kuş, Görkem; Demir, Gültekin Günhan; Sancar, Kadriye Memiç; Demirçelik, Muhammed Bora; Yanık, Ahmet; Akciğer, Atike Nazlı; Hoşcan, Yeşim; Arslan, Kürşat; Otlu, Yılmaz Ömür; Şahin, İsmail; Ersoy, İbrahim; YIlmaz, Dilek Çiçek; Mert, Kadir Uğur; Varim, Perihan; Arı, Hatem
    Objective: Heart failure (HF) has a high prevalence and mortality rate in elderly patients; however, there are few studies that have focused on patients older than 80 years. The aim of this study is to describe and compare the age-specific demographics and clinical features of Turkish elderly patients with HF who were admitted to cardiology clinics. Methods: The Epidemiology of Cardiovascular Disease in Elderly Turkish population (ELDER-TURK) study was conducted in 73 centers in Turkey, and it recruited a total of 5694 patients aged 65 years or older. In this study, the clinical profile of the patients who were aged 80 years or older and those between 65 and 79 years with HF were described and compared based on the ejection fraction (EF)-related classification: HFrEF and HFpEF (is considered as EF:>= 50%). Results: A total of 1098 patients (male, 47.5%; mean age, 83.5 +/- 3.1 years) aged 80 years and 4596 patients (male, 50.2 %; mean age, 71.1 +/- 4.31 years) aged 65-79 years were enrolled in this study. The prevalence of HF was 39.8% for patients who were>= 80 years and 27.1% for patients 65-79 years old. For patients aged>= 80 years with HF, the prevalence rate was 67% for hypertension (HT), 25.6% for diabetes mellitus (DM), 54.3% for coronary artery disease (CAD), and 42.3% for atrial fibrilation. Female proportion was lower in the HFrEF group (p=0.019). The prevalence of HT and DM was higher in the HFpEF group (p<0.01), whereas CAD had a higher prevalence in the HFrEF group (p=0.02). Among patients aged 65-79 years, 43.9% (548) had HFpEF, and 56.1% (700) had HFrEF. In this group of patients aged 65-79 years with HFrEF, the prevalence of DM was significantly higher than in patients aged>= 80 years with HFrEF (p<0.01). Conclusion: HF is common in elderly Turkish population, and its frequency increases significantly with age. Females, diabetics, and hypertensives are more likely to have HFpEF, whereas CAD patients are more likely to have HFrEF.
  • Küçük Resim
    Öğe
    Improvement of endothelial function early after thrombolytic therapy in patients with prosthetic heart valve thrombosis
    (Turkish Society of Cardiology, 2020) Çakal, Beytullah; Kalçık, Macit; Güner, Ahmet; Yesin, Mahmut; Gürsoy, Mustafa Ozan; Gündüz, Sabahattin; Karakoyun, Süleyman; Bayam, Emrah; Kalkan, Semih; Özkan, Mehmet
    Objective: Prosthetic valve thrombosis (PVT) is a serious complication among patients with prosthetic heart valves. Thrombolytic therapy (TT) is now widely used as first-line treatment for PVT. Endothelial dysfunction has previously been reported in patients with PVT. The aim of this study was to investigate the changes in endothelial function soon after TT in PVT patients.Methods: The study group included 85 patients with PVT [female: 53 (62.3%); age: 48.7 +/- 13.9 years] who were evaluated prospectively before and shortly after TT. All of the patients were evaluated using transthoracic and transesophageal echocardiography. TT was administered in all cases with a low-dose, ultra-slow infusion regimen. Endothelial function was evaluated using a noninvasive measurement of flow-mediated dilatation (FMD) of the brachial artery during reactive hyperemia.Results: The study population included 38 (44.7%) obstructive and 47 (55.3%) non-obstructive PVT patients. The obstructive PVT patients had lower baseline FMD values than the non-obstructive PVT group (5.31 +/- 0.76% vs. 5.87 +/- 0.84%; p=0.003). TT was successful in 79 patients (92.9%). FMD was significantly increased in the successfully thrombolyzed patients after TT (5.65 +/- 0.86% vs. 7.13 +/- 1.26%; p<0.001). There was no significant difference in the FMD values after TT in patients who were unresponsive to TT (5.07 +/- 0.61% vs. 5.38 +/- 0.95%; p=0.371). There was a significant increase in FMD values after TT in patients with obstructive PVT (5.31 +/- 0.76% vs. 8.22 +/- 1.15%; p<0.001). However, this difference was not statistically significant for patients with non-obstructive PVT (5.87 +/- 0.84% vs. 6.11 +/- 0.95%; p=0.276).Conclusion: This study demonstrated that successful TT may contribute to improvement of impaired endothelial function in patients with obstructive PVT.
  • Küçük Resim Yok
    Öğe
    The role of protein Z and protein Z-dependent protease inhibitor polymorphisms in the development of prosthetic heart valve thrombosis
    (2017) Karakoyun, Süleyman; Gürsoy, Mustafa Ozan; Kalçık, Macit; Yesin, Mahmut; Gündüz, Sabahattin; Astarcıoğlu, Mehmet Ali; Bayram, Zübeyde; Çakal, Beytullah; Bayam, Emrah; Özkan, Mehmet
    BACKGROUND AND AIM OF THE STUDY: Protein Z (PZ) is a vitamin K-dependent factor that is synthesized mainly by the liver. It acts as an activator of serpin, the protein Z-dependent inhibitor (ZPI), which inhibits factor Xa. The potential role of alterations in protein Z and/or ZPI levels in the pathogenesis of thrombotic and/or hemorrhagic diseases has been previously investigated, but results have been conflicting. The study aim was to evaluate the role of PZ/ZPI polymorphisms in the development of prosthetic valve thrombosis (PVT).METHODS: This prospective, observational cross-sectional study included 50 consecutive patients with PVT [non-obstructive thrombosis (NOT) in 35 patients; obstructive thrombosis (OT) in 15] and 50 consecutive healthy subjects with normally functioning prostheses. gDNA was extracted from ca. 5 × 106 leukocytes, using the QIAamp DNA Mini Kit (Qiagen), according to the manufacturer's recommendations. For mutational analysis, a minisequencing method was employed. Results of the analyses were compared between the PVT and control groups, and also between the OT and NOT subgroups.RESULTS: The frequency of A allele (mutant type) of PZG79A was equal in all PVT patients and in controls. With regards to PZ-A13G polymorphisms, frequency of the mutant G allele was 22% in PVT patients and 19% in controls. Serpina-R67X polymorphism was observed in 8% of PVT patients and 6% of controls. Normal variant CC was present in 47 controls (94%), whereas a heterozygotic mutation (CT) was detected in four PVT patients (8%). Frequency of the ZPI-R67X mutation was significantly higher in patients with OT than in those with NOT (p = 0.041).CONCLUSIONS: The present study was the first to evaluate the potential impact of PZ (PZ-A13G, PZG79A) and ZPI (R-67X, W303X) polymorphisms in the development of PVT. Based on the results of this small observational case-control study, PZ/ZPI polymorphisms do not appear to play an active role in the development of PVT. Hence, further extensive studies are necessary.